304 related articles for article (PubMed ID: 32050037)
1. Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study.
Shiha G; Mousa N; Soliman R; Nnh Mikhail N; Adel Elbasiony M; Khattab M
J Viral Hepat; 2020 Jul; 27(7):671-679. PubMed ID: 32050037
[TBL] [Abstract][Full Text] [Related]
2. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
[TBL] [Abstract][Full Text] [Related]
3. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals.
Alem SA; Eletreby R; Abdellatif Z; Ramadan A; Nagy A; AbdAllah M; Elsharkawy A; Fouad R; Esmat G; Tantawi O
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e746-e752. PubMed ID: 34231522
[TBL] [Abstract][Full Text] [Related]
7. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
Roche B; Coilly A; Duclos-Vallee JC; Samuel D
Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia.
Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841
[TBL] [Abstract][Full Text] [Related]
9. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
10. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
[TBL] [Abstract][Full Text] [Related]
12. Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study.
Li M; Li Y; Zhang Y; Wang X; Lin C
Medicine (Baltimore); 2024 Feb; 103(7):e37212. PubMed ID: 38363923
[TBL] [Abstract][Full Text] [Related]
13. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
14. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
15. Residual risk of hepatocellular carcinoma development for chronic hepatitis C patients treated by all oral direct-acting antivirals with sustained virological response.
Luan CH; Su PS; Chu CJ; Lin CC; Su CW; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC
J Chin Med Assoc; 2023 Sep; 86(9):795-805. PubMed ID: 37466658
[TBL] [Abstract][Full Text] [Related]
16. Shear-wave elastography to predict hepatocellular carcinoma after hepatitis C virus eradication: A systematic review and meta-analysis.
Esposto G; Santini P; Galasso L; Mignini I; Ainora ME; Gasbarrini A; Zocco MA
World J Gastroenterol; 2024 Mar; 30(10):1450-1460. PubMed ID: 38596502
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
Cordero-Ruiz P; Carmona-Soria I; Rodríguez-Téllez M; Caunedo-Alvarez A; Quezada-Pacheco RH; Flores-Cucho A; Romero-Gómez M; Vilches-Arenas Á
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):792-799. PubMed ID: 28445251
[TBL] [Abstract][Full Text] [Related]
18. Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
Piñero F; Mendizabal M; Ridruejo E; Herz Wolff F; Ameigeiras B; Anders M; Schinoni MI; Reggiardo V; Palazzo A; Videla M; Alonso C; Santos L; Varón A; Figueroa S; Vistarini C; Adrover R; Fernández N; Perez D; Tanno F; Hernández N; Sixto M; Borzi S; Bruno A; Cocozzella D; Soza A; Descalzi V; Estepo C; Zerega A; de Araujo A; Cheinquer H; Silva M;
Liver Int; 2019 Jun; 39(6):1033-1043. PubMed ID: 30636361
[TBL] [Abstract][Full Text] [Related]
19. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
[TBL] [Abstract][Full Text] [Related]
20. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
